Substituted quinolines as PDE-10 inhibitors

1. A compound of formula (I):

A-L-B   (I),

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

L is —C(R 6 ) 2 —C(R 6 ) 2 — or —(CH 2 ) u —;

A is

B is

-A 1 -A 2 - is —CR 8 ═CR 8 —;

A 3 is N;

A 4 is NR 5 , O, or S;

A 5 is CR 5 or N;

A 6 is N;

R 1 and R 2 together with the carbon atoms to which they are attached form a 1,2-phenylene ring optionally substituted with one or more R 11 ;

R 3 and R 4 are each independently (i) hydrogen, cyano, or halogen; or (ii) (C 1 -C 10 )alkyl, (C 2 -C 10 )alkenyl, (C 1 -C 10 ) alkoxy, (C 1 -C 10 )aminoalkyl, (C 1 -C 10 )heteroalkyl, (C 3 -C 10 )cycloalkyl, (6 to 10 membered)aryl, (5 to 10 membered)heteroaryl, (3 to 12 membered)heterocyclyl, hydroxy, amino, imino, amido, or thiol, each of which is optionally substituted with one or more R 11 ; or (iii) R 3 and R 4 together with the atoms to which they are attached form a ring optionally substituted with one or more R 11 ;

R 5 is (i) hydrogen, cyano, or halogen; or (ii) (C 2 -C 10 )alkenyl, (C 1 -C 10 )alkoxy, (C 1 -C 10 )aminoalkyl, (C 1 -C 10 )heteroalkyl, (C 3 -C 10 )cycloalkyl, (6 to 10 membered)aryl, (5 to 10 membered)heteroaryl, (3 to 12 membered)heterocyclyl, hydroxy, amino, imino, amido, or thiol, each of which is optionally substituted with one or more R 11 ; or (iii) R 4 and R 5 together with the atoms to which they are attached form a ring optionally substituted with one or more R 11 ;

R 19 is (i) hydrogen, cyano, or halogen; or (ii) (C 1 -C 10 )alkyl, (C 2 -C 10 )alkenyl, (C 1 -C 10 )alkoxy, (C 1 -C 10 )aminoalkyl, (C 1 -C 10 )heteroalkyl, (C 3 -C 10 )cycloalkyl, (6 to 10 membered)aryl, (5 to 10 membered)heteroaryl, (3 to 12 membered)heterocyclyl, hydroxy, amino, imino, amido, or thiol, each of which is optionally substituted with one or more R 11 ;

R 20 is (i) hydrogen; or (ii) (C 1 -C 10 )alkyl, (C 2 -C 10 )alkenyl, (C 1 -C 10 )heteroalkyl, (C 3 -C 10 )cycloalkyl, (6 to 10 membered)aryl, (5 to 10 membered)heteroaryl or (3 to 12 membered)heterocyclyl, each of which is optionally substituted with one or more R 11 ;

each occurrence of R 6 is independently hydrogen, halogen, or (C 1 -C 6 )alkyl optionally substituted with one or more halogen;

each occurrence of R 8 is independently (i) hydrogen, cyano, or halogen; or (ii) (C 1 -C 10 )alkyl, (C 2 -C 10 )alkenyl, (C 1 -C 10 ) alkoxy, (C 1 -C 10 )aminoalkyl, (C 1 -C 10 )heteroalkyl, (C 3 -C 10 )cycloalkyl, (6 to 10 membered)aryl, (5 to 10 membered)heteroaryl, (3 to 12 membered) heterocyclyl, hydroxy, amino, imino, amido, or thiol, each of which is optionally substituted with one or more R 11 ;

each occurrence of R 11 is independently halogen, cyano, —OR 13 , —N(R 13 )C(O)R 14 , —C(O)NR 13 R 14 , —C(O)R 13 , —C(O)OR 13 , —OC(O)OR 13 , —SR 13 , —S(O)R 13 , —S(O) 2 R 13 , —S(O) 2 NR 13 R 14 , (C 1 -C 10 )alkyl optionally substituted with one or more R 12 , (C 1 -C 10 )heteroalkyl optionally substituted with one or more R 12 , (C 3 -C 10 )cycloalkyl optionally substituted with one or more R 12 , (C 7 -C 12 )aralkyl optionally substituted with one or more R 12 , (C 3 -C 12 )heteroaralkyl optionally substituted with one or more R 12 , (6 to 10 membered)aryl optionally substituted with one or more R 12 , (5 to 10 membered)heteroaryl optionally substituted with one or more R 12 , or (3 to 12 membered)heterocyclyl optionally substituted with one or more R 12 ;

each occurrence of R 12 is independently (C 1 -C 6 )alkyl optionally substituted with one or more R 13 , (C 3 -C 6 )cycloalkyl optionally substituted with one or more R 13 , halogen, cyano, ═O, —OR 13 , —NR 13 R 14 , —N(R 13 )C(O)R 14 , —C(O)NR 13 R 14 , —C(O)R 13 , —C(O)OR 13 , —OC(O)R 13 , —SR 13 , —S(O)R 13 , —S(O) 2 R 13 , or —S(O) 2 NR 13 R 14 ;

each occurrence of R 13 and R 14 is independently hydrogen, (C 1 -C 6 )alkyl, (C 1 -C 6 )heteroalkyl, (C 3 -C 6 )cycloakyl, (C 7 -C 10 )aralkyl; (C 3 -C 12 )heteroaralkyl, (6 to 10 membered)aryl, (5 to 10 membered)heteroaryl, or (3 to 12 membered)heterocyclyl; or R 13 and R 14 together may form a 3 to 10 membered ring; and

u 3.

2. The compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound has formula (I-A):

3. The compound of claim 2 , wherein

and

k is 0, 1, 2, 3, or 4.

4. The compound of claim 3 , wherein R 3 is (i) hydrogen; or (ii) (C 1 -C 10 )alkyl, (6 to 10 membered)aryl, or (5 to 10 membered)heteroaryl, each of which is optionally substituted with one or more R 11 .

5. The compound of claim 3 , wherein R 4 is (i) hydrogen; or (ii) (C 1 -C 10 )alkyl, (6 to 10 membered)aryl, or (5 to 10 membered)heteroaryl, each of which is optionally substituted with one or more R 11 .

6. The compound of claim 3 , wherein R 5 is (i) hydrogen; or (ii) (C 1 -C 10 )alkyl, (6 to 10 membered)aryl, or (5 to 10 membered)heteroaryl, each of which is optionally substituted with one or more R 11 .

7. The compound of claim 3 , wherein each occurrence of R 11 is independently (C 1 -C 10 )alkyl, (6 to 10 membered)aryl or (5 to 10 membered)heteroaryl, each of which is optionally substituted with one or more R 12 .

8. The compound of claim 2 , wherein A 4 is NR 5 ; and R 5 is (i) hydrogen; or (ii) (C 1 -C 10 )alkyl, (C 2 -C 10 )alkenyl, (C 1 -C 10 )heteroalkyl, (C 3 -C 10 )cycloalkyl, (6 to 10 membered) aryl, (5 to 10 membered) heteroaryl or (3 to 12 membered)heterocyclyl, each of which is optionally substituted with one or more R 11 ; or (iii) R 4 and R 5 together with the atoms to which they are attached form a ring optionally substituted with one or more R 11 .

9. The compound of claim 8 , wherein R 5 is hydrogen or CH 3 .

10. The compound of claim 2 , wherein

11. The compound of claim 2 , wherein

each occurrence of R 15 is independently: (i) hydrogen, halogen, cyano, —OR 13 , —N(R 13 )C(O)R 14 , —C(O)NR 13 R 14 , —C(O)R 13 , —C(O)OR 13 , —OC(O)R 13 , —SR 13 , —S(O)R 13 , —S(O) 2 R 13 , —S(O) 2 NR 13 R 14 , (C 1 -C 10 )alkyl optionally substituted with one or more R 12 , (C 1 -C 10 )heteroalkyl optionally substituted with one or more R 12 , (C 3 -C 10 )cycloalkyl optionally substituted with one or more R 12 , (C 7 -C 12 )aralkyl optionally substituted with one or more R 12 , (C 3 -C 12 )heteroaralkyl optionally substituted with one or more R 12 , (6 to 10 membered)aryl optionally substituted with one or more R 12 , (5 to 10 membered)heteroaryl optionally substituted with one or more R 12 , or (3 to 12 membered)heterocyclyl optionally substituted with one or more R 12 ; and

m is 0, 1, 2, 3, or 4.

12. The compound of claim 11 , wherein the compound is:

13. The compound of claim 1 , wherein B is

wherein each R 11 may be the same or different.

14. The compound of claim 1 , wherein

B is

15. The compound of claim 1 , wherein L is —CH 2 —CH 2 —.

16. The compound of claim 1 , wherein R 1 and R 2 together with the carbon atoms to which they are attached form an unsubstituted 1,2-phenylene ring.

17. The compound of claim 1 , wherein R 1 and R 2 together with the carbon atoms to which they are attached form a 1,2-phenylene ring substituted with one or more R 11 .

18. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, and at least one pharmaceutically acceptable excipient, diluent, or carrier.

19. The pharmaceutical composition of claim 18 , wherein the pharmaceutical composition further comprises one or more additional active agents.

20. A method of inhibiting phosphodiesterase-10A activity in a subject, comprising administering to a subject a therapeutically or prophylactically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof.

21. The method of claim 20 , wherein the subject suffers from a neurological disorder, a schizophrenia-related disorder, a disease having a psychosis component, a psychotic disorder, a behavior disorder, a neurodegenerative disease, a mood disorder, a manic disorder, a movement disorder, a sleep disorder, an addiction or an eating disorder.

22. The method of claim 20 , wherein the subject suffers from schizophrenia, schizophrenia spectrum disorder, schizoaffoctive disorder, schizophreniform disorder, paraphrenia, paranoid personality disorder, schizoid personality disorder, schizotypal personality disorder, delusional disorder, psychosis, psychoaffective disorder, aggression, delirium, Tourette's syndrome, convulsion, seizure, agitation, posttraumatic stress disorder, Huntington's disease, Alzheimer's disease, Parkinson's disease, dyskinesia, dementia, bipolar disorder, anxiety, depression, major depressive disorder, dysthymia, affective disorder, obsessive-compulsive disorder, attention deficit disorder, attention deficit hyperactivity disorder, vertigo, pain, sensitization accompanying neuropathic pain, fibromyalgia, migraine, cognitive impairment, cognitive deficit in Alzheimer's disease, cognitive deficit in Parkinson's disease, restless leg syndrome, multiple sclerosis, substance abuse, substance dependency, autism, obesity, undesirable weight retention, undesirable weight gain, metabolic syndrome, diabetes, impaired glucose tolerance or hyperglycemia.

23. The method of claim 22 , wherein the schizophrenia, psychosis, psychotic disorder, depression, affective disorder, pain, cognitive impairment or diabetes is selected from the group consisting of acute schizophrenia, chronic schizophrenia, not otherwise specified schizophrenia, Alzheimer's psychosis, Parkinson's psychosis, excitative psychosis, organic psychosis, not otherwise specified psychosis, brief psychotic disorder, shared psychotic disorder, substance-induced psychotic disorder, psychotic disorder due to a general medical condition, unipolar depression, treatment resistant depression, seasonal affective disorder, neuropathic pain, inflammatory pain, cognitive impairment associated with schizophrenia and non-insulin dependent diabetes.

24. The method of claim 20 , wherein the subject suffers from a central nervous system disorder.

25. The method of claim 20 , wherein the subject suffers from a metabolic disorder.

26. The method of claim 20 , wherein the subject is a human.

27. A compound of formula (I-B):

D-L-E   (I-B),

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

L is —C(R 6 ) 2 —C(R 6 ) 2 or —(CH 2 ) u —;

R 6 is hydrogen;

D is

E is

each Y is independently N or CR;

each Z is independently N or C, wherein at least one occurrence of Z is C;

provided that D contains 1, 2, 3, or 4 nitrogen ring atoms;

each occurrence of R is independently hydrogen, halogen, cyano, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, (C 1 -C 6 )hydroxyalkyl, (6 to 10 membered)aryl, or (5 to 10 membered)heteroaryl;

each occurrence of R 21 , R 22 , R 23 , and R 24 is independently hydrogen, halogen, cyano, (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 1 -C 6 )heteroalkyl, (C 1 -C 6 )alkoxy, (C 1 -C 6 )aminoalkyl, (C 1 -C 6 )hydroxyalkyl, CH 2 CN, CH 2 C(O)NH 2 , (C 3 -C 8 )cycloalkyl, (6 to 10 membered)aryl, (5 to 10 membered)heteroaryl, (3 to 12 membered)heterocyclyl, (C 7 -C 12 )aralkyl, (C 3 -C 12 )heteroaralkyl, or (C 1 -C 10 )alkyl-heterocycloalkyl;

R 25 is hydrogen, halogen, cyano, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 6 )alkoxy, (C 1 -C 6 )hydroxyalkyl, CH 2 CN, CH 2 C(O)NH 2 , (C 7 -C 12 )aralkyl, or (C 1 -C 10 )alkyl-heterocycloalkyl; and

u is 3.

28. The compound of claim 25 , wherein D is:

29. The compound of claim 27 , wherein D is:

30. The compound of claim 27 , wherein L is —CH 2 —CH 2 —O—CH 2 .

31. The compound of claim 27 , wherein L is —CH 2 —CH 2 —.

32. The compound of claim 27 , wherein the compound is: